Weight loss jabs: What happens when you stop taking them?

GLP‑1 weight‑loss drugs (examples: Wegovy by Novo Nordisk and Mounjaro by Eli Lilly) are producing large individual weight reductions—patients in the piece reported losses of ~38kg and ~51kg—and an estimated 1.5 million people in the UK pay for injections privately. Clinical uncertainty and dependence are salient risks: clinicians cite rapid return of appetite and evidence suggesting 60–80% of lost weight can return within 1–3 years after stopping, and NICE recommends at least a year of post‑treatment support. For investors, strong consumer demand and recurring private-pay use suggest upside to manufacturers' revenue prospects, but regulatory scrutiny, safety/side‑effect profiles and adherence challenges create material longer‑term uptake and pricing risk.

Analysis

Market structure: GLP‑1 obesity drugs crystallize a multi-year, high-margin recurring‑revenue market for large-cap pharmas (NVO, LLY). Winners are scale incumbents with manufacturing capacity, IP and chronic‑use pricing power; losers include elective bariatric surgery volumes, some quick‑service dining segments and small private clinics reliant on one-off scripts. Expect sustained private demand in 2026–27 with pricing resilience that supports 20–40% revenue CAGR in obesity franchises vs. broader pharma.

Risk assessment: Key tail risks are regulatory/payer pushback or a class‑wide safety signal that could remove reimbursement (scenario: 30–60% hit to obesity revenue within 3–12 months). Supply chain/manufacturing bottlenecks are medium probability but can cap sales for 1–4 quarters. Catalysts include long‑term safety data, FDA/EMA label updates and major insurer coverage decisions over the next 3–12 months.

Trade implications: Favor large‑cap, high‑margin producers; trade around 3–9 month catalysts with protected upside (buy spreads or long stock + hedges). Avoid long‑only exposure to consumer foodservice names without hedges; rotate 1–3% AUM from discretionary into healthcare large‑caps over 3–12 months. Use options to express asymmetric bets ahead of earnings/regulatory dates.

Contrarian angles: Consensus underestimates chronic use economics and stickiness — many patients will remain on therapy, supporting higher lifetime revenue per patient vs one‑time interventions. Overdone risks are binary safety fears; underdone is payer fatigue — pricing may compress only if multiple payers restrict coverage, which would take 6–18 months to materialize. Historical parallel: insulin pricing debates show regulation risk is real but gradual, not instantaneous.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) within 30 days to capture obesity franchise growth; target 12‑month upside of 20–35% and set a tactical stop at −15% or hedge with a 6‑9 month 10–12% OTM put if implied volatility is <30%.
• Add a 1–2% tactical long in LLY (Eli Lilly) via a 6‑9 month bull call spread (cost‑limited) to participate in tirzepatide adoption; unwind on a negative safety/regulatory signal or on >15% adverse move pre/post earnings (within 60–90 days).
• Implement a relative‑value pair: long NVO vs short MCD (McDonald's) equal dollar for 6–12 months to express secular advantage of GLP‑1s over casual dining; close if the pair diverges >10% adverse or upon insurer coverage expansion for prescriptions.
• Reduce consumer discretionary/restaurant exposure by 1–2% AUM over the next quarter and reallocate to healthcare large‑caps; if a major payer restricts coverage or a class safety alert occurs within 30–90 days, cut NVO/LLY exposure by 50% within 48 hours.